Literature DB >> 32779267

Brain delivery of biologics using a cross-species reactive transferrin receptor 1 VNAR shuttle.

Dag Sehlin1, Pawel Stocki2,3, Tobias Gustavsson1, Greta Hultqvist4, Frank S Walsh2,3, J Lynn Rutkowski2,3, Stina Syvänen1.   

Abstract

Transferrin receptor 1 (TfR1) mediated transcytosis is an attractive strategy to enhance brain uptake of protein drugs, but translation remains a challenge. Here, a single domain shark antibody VNAR fragment (TXB2) with similar affinity to murine and human TfR1 was used to shuttle protein cargo into the brain. TXB2 was fused to a human IgG1 Fc domain (hFc) or to the amyloid-β (Aβ) antibody bapineuzumab (Bapi). TXB2-hFc displayed 20-fold higher brain concentrations compared with a control VNAR-hFc at 18 hours post-injection in wt mice. At the same time point, brain concentrations of Bapi-TXB2 was threefold higher than Bapi. In transgenic mice overexpressing human Aβ, the brain-to-blood concentration ratio increased with time due to interaction with intracerebral Aβ deposits. The relatively stable threefold difference between Bapi-TXB2 and Bapi was observed for up to 6 days after injection. PET imaging and ex vivo autoradiography revealed more parenchymal distribution of Bapi-TXB2 compared with Bapi. In conclusion, the TXB2 VNAR shuttle markedly increased brain uptake of protein cargo and increased brain concentrations of the Aβ binding antibody Bapi.
© 2020 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.

Entities:  

Keywords:  Alzheimer's disease (AD); amyloid-β (Aβ); antibody; blood-brain barrier (BBB); positron emission tomography (PET); receptor mediated transcytosis

Year:  2020        PMID: 32779267     DOI: 10.1096/fj.202000610RR

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  10 in total

Review 1.  A Historical Review of Brain Drug Delivery.

Authors:  William M Pardridge
Journal:  Pharmaceutics       Date:  2022-06-16       Impact factor: 6.525

2.  Transferrin Receptor Binding BBB-Shuttle Facilitates Brain Delivery of Anti-Aβ-Affibodies.

Authors:  Rebecca Faresjö; Hanna Lindberg; Stefan Ståhl; John Löfblom; Stina Syvänen; Dag Sehlin
Journal:  Pharm Res       Date:  2022-05-10       Impact factor: 4.580

3.  Fluorine-18-Labeled Antibody Ligands for PET Imaging of Amyloid-β in Brain.

Authors:  Stina Syvänen; Xiaotian T Fang; Rebecca Faresjö; Johanna Rokka; Lars Lannfelt; Dag E Olberg; Jonas Eriksson; Dag Sehlin
Journal:  ACS Chem Neurosci       Date:  2020-11-25       Impact factor: 4.418

4.  A Single Domain Shark Antibody Targeting the Transferrin Receptor 1 Delivers a TrkB Agonist Antibody to the Brain and Provides Full Neuroprotection in a Mouse Model of Parkinson's Disease.

Authors:  Emily Clarke; Pawel Stocki; Elizabeth H Sinclair; Aziz Gauhar; Edward J R Fletcher; Alicja Krawczun-Rygmaczewska; Susan Duty; Frank S Walsh; Patrick Doherty; Julia Lynn Rutkowski
Journal:  Pharmaceutics       Date:  2022-06-24       Impact factor: 6.525

5.  VHHs as tools for therapeutic protein delivery to the central nervous system.

Authors:  Yessica Wouters; Tom Jaspers; Laura Rué; Lutgarde Serneels; Bart De Strooper; Maarten Dewilde
Journal:  Fluids Barriers CNS       Date:  2022-10-03

6.  Brain pharmacokinetics of two BBB penetrating bispecific antibodies of different size.

Authors:  Rebecca Faresjö; Gillian Bonvicini; Xiaotian T Fang; Ximena Aguilar; Dag Sehlin; Stina Syvänen
Journal:  Fluids Barriers CNS       Date:  2021-06-02

Review 7.  Current and Emerging Strategies for Enhancing Antibody Delivery to the Brain.

Authors:  Rinie Bajracharya; Alayna C Caruso; Laura J Vella; Rebecca M Nisbet
Journal:  Pharmaceutics       Date:  2021-11-26       Impact factor: 6.321

Review 8.  Kinetics of Blood-Brain Barrier Transport of Monoclonal Antibodies Targeting the Insulin Receptor and the Transferrin Receptor.

Authors:  William M Pardridge
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-21

9.  Pinpointing Brain TREM2 Levels in Two Mouse Models of Alzheimer's Disease.

Authors:  Silvio R Meier; Dag Sehlin; Greta Hultqvist; Stina Syvänen
Journal:  Mol Imaging Biol       Date:  2021-02-23       Impact factor: 3.488

10.  11C-PiB and 124I-Antibody PET Provide Differing Estimates of Brain Amyloid-β After Therapeutic Intervention.

Authors:  Silvio R Meier; Dag Sehlin; Sahar Roshanbin; Victoria Lim Falk; Takashi Saito; Takaomi C Saido; Ulf Neumann; Johanna Rokka; Jonas Eriksson; Stina Syvänen
Journal:  J Nucl Med       Date:  2021-06-04       Impact factor: 10.057

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.